RISK FACTORS OR PREDICTORS OF DEVELOPING CIPROFLOXACIN, TRIMETHOPRIM/SULFAMETHOXAZOLE AND THIRD GENERATION CEPHALOSPORIN RESISTANCE IN ESCHERICHIA COLI INFECTIONS: A SYSTEMATIC REVIEW AND META-ANALYSIS

The Centers for Disease Control and Prevention (CDC) estimates that by 2050, ten million people a year could be dying as result of Anti-Microbial Resistance (AMR). An increase in resistance has been observed trimethoprim/sulfamethoxazole followed ciprofloxacin third-generation cephalosporins the management Escherichia coli infections. To identify risk factors (Cip-REC), (TMP/SMX-REC,) cephalosporin (TGC-REC) infection relative to controls patients. A systematic search MEDLINE/PubMed Embase databases identified case-control, cohort, cross-sectional studies on Cip-REC, TMP/SMX-REC, TGC-REC-infected random-effects model was used pool odds ratios (ORs) developing resistant E. infection. This study registered with PROSPERO (CRD42022297043). total 23 were included (9891 participants). Overall, 22, 8, 11 TGC-REC infections respectively. prior antibiotic use [OR=3.19] reported high pooled ORs Cip-REC TMP/SMX-REC associated genitourinary abnormalities [OR=2.91]. Further analysis unveiled potential infection; history admission [OR=3.14] hemodialysis [OR=2.20]. Prior usage, disorders, Modifiable may help prevent KEYWORDS: coli, Ciprofloxacin, Trimethoprim, Sulfamethoxazole, Third Generation Cephalosporin